M4MM

DEA Opens Schedule III Registration Path for Medical Cannabis Operators

WASHINGTON – The Drug Enforcement Administration’s Diversion Control Division has launched the application process, making DEA Form 225 available to state-licensed medical Cannabis manufacturers, distributors, and analytical labs. Manufacturers cover cultivation, production, processing, packaging, labeling ...

Nasdaq’s $5M Delisting Rule: Frozen, Not Finished

WASHINGTON – The Securities and Exchange Commission (SEC) approved a new Nasdaq listing requirement on July 22, stayed it seven days later after receiving petitions, and on September 11 formally granted those petitions for full ...

DEA Opens Schedule III Registration Path for Medical Cannabis Operators

WASHINGTON – The Drug Enforcement Administration’s Diversion Control Division has launched the application process, making DEA Form 225 available to state-licensed medical Cannabis manufacturers, distributors, and analytical labs. Manufacturers cover cultivation, production, processing, packaging, labeling ...

Optimi Ships Psilocybin to the UK for Phase 2 Trial

VANCOUVER – Optimi Health Corp. announced it has completed its first export of naturally derived psilocybin to the United Kingdom, with the material earmarked for a planned Phase 2 clinical trial whose partner and therapeutic ...

Trulieve Announces Share Buyback Program

TALLAHASSEE – Trulieve Cannabis Corp. announced that its Board of Directors has authorized a share repurchase program, allowing the company to buy back up to the lesser of $50 million in aggregate value or 8,495,038 ...

Cross-Border Deals Now Define Cannabis M&A

LOS ANGELES – The global Cannabis industry has entered a new phase, one where the most influential deals are no longer being struck in North America, but across continents. The month of June kicked off ...

Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Highly Capitalized Network-HCN tracked meaningful steps in operational strengthening, capital readiness, and program performance across the Cannabis and Psychedelics sectors during the past two weeks. The capital markets finally spoke, and they ...

Psilocybin Shows Promise in Treating Cocaine Addiction

BIRMINGHAM – For the first time, a peer-reviewed, randomized clinical trial showed that psilocybin significantly reduced cocaine use when combined with structured psychotherapy. The findings, published in JAMA Network Open by researchers at the University ...

Subscribe To Our Newsletter